Ameriprise Financial Trims Bristol Myers Squibb Holdings

Institutional investor reduces stake in biopharmaceutical company

Mar. 15, 2026 at 7:45am

Got story updates? Submit your updates here. ›

Ameriprise Financial Inc. trimmed its holdings in Bristol Myers Squibb Company by 0.3% in the 3rd quarter, according to a disclosure with the Securities & Exchange Commission. The institutional investor owned 32,473,834 shares of the biopharmaceutical company's stock worth $1,464,552,000 as of its most recent SEC filing.

Why it matters

This filing provides insight into the investment decisions of a major institutional investor, Ameriprise Financial, and their view on the prospects of Bristol Myers Squibb, a leading biopharmaceutical company. Tracking changes in institutional ownership can offer clues about market sentiment and future performance of a stock.

The details

Ameriprise Financial reduced its stake in Bristol Myers Squibb by selling 105,784 shares during the 3rd quarter. Despite the slight decrease, Ameriprise Financial remained a significant shareholder, owning 1.60% of Bristol Myers Squibb's outstanding shares.

  • Ameriprise Financial trimmed its holdings in Bristol Myers Squibb in the 3rd quarter of 2026.

The players

Ameriprise Financial Inc.

A major institutional investor and financial services firm headquartered in Minneapolis, Minnesota.

Bristol Myers Squibb Company

A leading biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the ongoing interest and investment activity of major institutional investors like Ameriprise Financial in the biopharmaceutical sector, particularly around companies like Bristol Myers Squibb that are developing innovative therapies. Tracking changes in institutional ownership can provide valuable insights into market sentiment and potential future performance of these stocks.